Companies Coherus Oncology, Inc.
Coherus Oncology (CHRS): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Coherus Oncology, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers20th pct.Of 40 peer CEOs
CEO pay, last three years
- $5,897,924FY2023
- $4,802,309FY2024
- $2,736,874FY2025
CEO total pay was $2,736,874 in fiscal 2025, down from $4,802,309 in fiscal 2024.
FY2025: salary $1,026,545 · bonus $0 · stock awards $0 · option awards $828,130
Executives and directors
Bryan McMichael · CFOPaul Reider · CCODennis Lanfear · CEOAli J. Satvat · Independent DirectorCharles W. Newton · Independent DirectorGeorgia Erbez · Independent DirectorJill O'Donnell-Tormey, Ph.D · Independent DirectorLee N. Newcomer, MD · Independent DirectorMark D. Stolper · Former director (through FY2025)Mats L. Wahlström · Lead Independent DirectorMichael Ryan · Independent DirectorRita A. Karachun · Independent Director
Frequently asked questions
Who was the highest-paid executive at Coherus Oncology, Inc. in fiscal 2025?
As disclosed, Dennis Lanfear (President, Chief Executive Officer and Chairman of the Board of Directors) was the highest-paid executive at Coherus Oncology, Inc. in fiscal 2025, with total compensation of $2,736,874.
How does Coherus Oncology, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Dennis Lanfear's total compensation ranked at the 20th percentile of Coherus Oncology, Inc.'s disclosed peer group.
How did shareholders vote on Coherus Oncology, Inc.'s executive compensation?
As disclosed, 87.1% of shareholders supported Coherus Oncology, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Coherus Oncology, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Coherus Oncology, Inc. reported total board compensation of $664,375 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Dennis Lanfear | $1,026,545 | $0 | $0 | $828,130 | $869,295 | $0 | $12,904 | $2,736,874 |
| President, Chief Executive Officer and Chairman of the Board of Directors | ||||||||
| Paul Reider | 217,742 | 0 | 0 | 347,760 | 0 | 0 | 662,022 | 1,227,524 |
| Former Chief Commercial Officer | ||||||||
| Bryan McMichael | 543,688 | 0 | 0 | 314,192 | 237,697 | 0 | 7,500 | 1,103,077 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Dennis Lanfear | $2,736,874 | $4,802,309 | $5,897,924 | ↓ −2,065,435 |
| Paul Reider | 1,227,524 | 1,657,415 | 1,930,559 | ↓ −429,891 |
| Bryan McMichael | 1,103,077 | 1,032,870 | 1,070,218 | ↑ +70,207 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The key objective in our executive compensation program is to attract, motivate and reward leaders with the skills and experience necessary to successfully execute on our strategic plan to maximize stockholder value. The program is designed to attract and retain talented executives, motivate them to achieve the best possible financial and operational results, provide reward opportunities consistent with short-term and long-term performance, and align the long-term interests of our NEOs with those of our stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | — |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Bryan McMichael | OPTION | — | — | — | — | — | $314,192 |
| Paul Reider | OPTION | — | — | — | — | — | 347,760 |
| Dennis Lanfear | OPTION | — | — | — | — | — | 828,130 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Bryan McMichael | $0 | $0 | $314,192 | 0.0% |
| Paul Reider | 0 | 0 | 347,760 | 0.0% |
| Dennis Lanfear | 0 | 0 | 828,130 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Bryan McMichael | Option | 521 | 14.67 | — |
| Paul Reider | Option | 782 | 15.94 | — |
| Bryan McMichael | Option | 2,813 | 10.78 | — |
| Bryan McMichael | RSU | 4,166 | — | 5,916 |
| Bryan McMichael | Option | 6,771 | 9.87 | — |
| Bryan McMichael | Option | 7,813 | 6 | — |
| Dennis Lanfear | Option | 8,386 | 15.94 | — |
| Paul Reider | RSU | 13,333 | — | 18,933 |
| Paul Reider | Option | 21,667 | 9.87 | — |
| Dennis Lanfear | RSU | 28,750 | — | 40,825 |
| Bryan McMichael | Option | 50,000 | 1.24 | — |
| Bryan McMichael | Option | 65,105 | 3.14 | — |
| Paul Reider | Option | 83,334 | 3.14 | — |
| Dennis Lanfear | Option | 109,011 | 10.37 | — |
| Bryan McMichael | Option | 160,000 | 1.66 | — |
| Paul Reider | Option | 160,000 | 1.66 | — |
| Bryan McMichael | Option | 200,000 | 0.95 | — |
| Dennis Lanfear | Option | 299,480 | 3.14 | — |
| Dennis Lanfear | Option | 375,000 | 0.95 | — |
| Dennis Lanfear | Option | 575,000 | 1.47 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Mats L. WahlströmIndependent · Lead Independent Director · Audit · Nominating/Governance · Strategic Transaction (Chair) | $130,000 | — | $61,667 | — | — | $191,667 |
| Charles W. NewtonIndependent · Compensation (Chair) · Strategic Transaction | 82,500 | — | 61,667 | — | — | 144,167 |
| Ali J. SatvatIndependent · Audit · Nominating/Governance (Chair) · Strategic Transaction | 82,500 | — | 61,667 | — | — | 144,167 |
| Rita A. KarachunIndependent · Audit (Chair) | 77,500 | — | 61,667 | — | — | 139,167 |
| Georgia ErbezIndependent · Audit · Not standing for re-election | 72,500 | — | 61,667 | — | — | 134,167 |
| Michael RyanIndependent · Compensation · Strategic Transaction | 69,375 | — | 61,667 | — | — | 131,042 |
| Lee N. Newcomer, MDIndependent · Compensation | 60,000 | — | 61,667 | — | — | 121,667 |
| Jill O'Donnell-Tormey, Ph.DIndependent · Nominating/Governance | 55,000 | — | 61,667 | — | — | 116,667 |
| Mark D. StolperIndependent · Not standing for re-election · Departed during FY | 35,000 | — | 0 | — | — | 35,000 |
| Dennis M. LanfearEmployee director · Board Chair | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 20,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $664,375 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $664,375 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Coherus Oncology as a peer
Companies that benchmark against CHRS
14 companies name CHRS as a compensation peer
- Adaptimmune Therapeutics PLCADAPFY2024
- Akebia Therapeutics, Inc.AKBAFY2025
- AMARIN CORP PLC\UKAMRNFY2025
- Evolus, Inc.EOLSFY2025
- GERON CORPGERNFY2025
- HERON THERAPEUTICS, INC. /DE/HRTXFY2025
- Innoviva, Inc.INVAFY2025
- Kodiak Sciences Inc.KODFY2025
- MYRIAD GENETICS INCMYGNFY2025
- OMEROS CORPOMERFY2025
- PUMA BIOTECHNOLOGY, INC.PBYIFY2025
- RIGEL PHARMACEUTICALS INCRIGLFY2025
- Travere Therapeutics, Inc.TVTXFY2025
- Xeris Biopharma Holdings, Inc.XERSFY2025
Each company listed discloses CHRS in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CHRS in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy, which names it the “new peer group (2026 compensation decisions)” and “peer group used for 2025 compensation” and “Updated Peer Group” and “2025 Compensation Peer Group” — the reference set behind the percentile above.
CGEM Cullinan TherapeuticsOLMA Olema PharmaceuticalsCATX Perspective TherapeuticsACAD ACADIA PharmaceuticalsAGIO Agios PharmaceuticalsCOLL Collegium Pharmaceuticals FibrogenHRTX Heron TherapeuticsIRWD Ironwood PharmaceuticalsKPTI Karyopharm TherapeuticsMIRM Mirum PharmaceuticalsPCRX Pacira BioSciencesPTCT PTC TherapeuticsPBYI Puma BiotechnologySUPN Supernus PharmaceuticalsACTU Actuate TherapeuticsCRDF Cardiff OncologyCRBU Caribou BiosciencesLYEL Lyell ImmunopharmaPLRX Pliant TherapeuticsPGEN PrecigenREPL Replimune GroupXNCR XencorCRBU Caribou Biosciences Amicus PharmaceuticalsKPTI Karyopharm TherapeuticsREPL Replimune GroupCGEM Cullinan TherapeuticsHRTX Heron TherapeuticsOLMA Olema PharmaceuticalsAGIO Agios PharmaceuticalsCATX Perspective TherapeuticsMIRM Mirum PharmaceuticalsACAD ACADIA PharmaceuticalsPCRX Pacira BioSciencesBDTX Black Diamond TherapeuticsVNDA Vanda PharmaceuticalsXNCR XencorPLRX Pliant TherapeuticsSUPN Supernus Pharmaceuticals
Peer reciprocity
The companies Coherus Oncology, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | PTC Therapeutics | 2025 | Matthew Klein | $958,500 | $16,593,800 | $4,399,760 | $1,294,000 | $23,266,326 |
| 2 | Supernus Pharmaceuticals | 2025 | Joe Ciaffoni | 680,114 | 15,319,404 | 0 | 2,100,000 | 18,501,214 |
| 3 | Pacira BioSciences | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 4 | Mirum Pharmaceuticals | 2025 | Christopher Peetz | 755,000 | 3,683,904 | 4,931,320 | 1,057,000 | 10,441,224 |
| 5 | Acadia Pharmaceuticals | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 6 | Replimune Group | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
| 7 | Xencor | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 8 | Pliant Therapeutics | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 9 | Agios Pharmaceuticals | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
| 10 | Precigen | 2025 | Helen Sabzevari | 1,000,000 | 2,215,000 | 1,069,200 | 1,049,997 | 5,354,329 |
| 11 | Cullinan Therapeutics | 2025 | Nadim Ahmed | 698,476 | 1,697,400 | 2,234,340 | 419,086 | 5,100,006 |
| 12 | Lyell Immunopharma | 2025 | Lynn Seely | 690,173 | 186,806 | 2,907,551 | 414,000 | 4,222,265 |
| 13 | Vanda Pharmaceuticals | 2025 | Mihael Polymeropoulos | 965,655 | 2,007,000 | 0 | 834,326 | 3,851,468 |
| 14 | Heron Therapeutics | 2025 | Craig Collard | 689,431 | 946,254 | 1,352,917 | 517,189 | 3,516,291 |
| 15 | Olema Pharmaceuticals | 2025 | Sean Bohen | 699,920 | 0 | 2,002,000 | 461,900 | 3,178,990 |
| 16 | Puma Biotechnology | 2025 | Alan Auerbach | 931,333 | 551,549 | 535,513 | 1,027,307 | 3,062,337 |
| 17 | Cardiff Oncology | 2025 | Mark Erlander | 635,000 | 0 | 2,266,106 | 122,238 | 3,023,344 |
| 18 | Coherus Oncology, Inc. | 2025 | Dennis Lanfear | 1,026,545 | 0 | 828,130 | 869,295 | 2,736,874 |
| 19 | Perspective Therapeutics | 2025 | Johan Spoor | 680,000 | 0 | 1,302,692 | 408,000 | 2,404,692 |
| 20 | Karyopharm Therapeutics | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 21 | Black Diamond Therapeutics | 2025 | Mark Velleca | 667,400 | 189,000 | 1,006,030 | 348,717 | 2,234,919 |
| 22 | Actuate Therapeutics | 2025 | Daniel Schmitt | 570,000 | 0 | 1,454,193 | 0 | 2,166,522 |
| 23 | Ironwood Pharmaceuticals | 2025 | Thomas McCourt | 867,568 | 411,696 | 0 | 650,676 | 1,948,390 |
| 24 | Caribou Biosciences | 2025 | Rachel Haurwitz | 667,534 | 192,818 | 654,541 | 0 | 1,840,965 |
| 25 | Collegium Pharmaceuticals | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Coherus Oncology, Inc. | not disclosed | Option 100 | not disclosed | Aon |
| Acadia Pharmaceuticals | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Actuate Therapeutics | not disclosed | Options 100 | not disclosed | Anderson Pay Advisors LLC |
| Agios Pharmaceuticals | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Black Diamond Therapeutics | 95% | not disclosed | not disclosed | Aon Human Capital Solutions (Aon plc) |
| Cardiff Oncology | 35% | Option 100 | not disclosed | Aon |
| Caribou Biosciences | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Collegium Pharmaceuticals | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Cullinan Therapeutics | not disclosed | not disclosed | not disclosed | Compensia (through June 2025); Pay Governance (since June 2025) |
| Heron Therapeutics | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Compensia, Inc. |
| Ironwood Pharmaceuticals | 100% | RSU 50 · PSU 50 | not disclosed | Alpine Rewards LLC |
| Karyopharm Therapeutics | 90% | not disclosed | Yes — Relative TSR | Alpine, WTW |
| Lyell Immunopharma | 100% | not disclosed | No | Alpine |
| Mirum Pharmaceuticals | 200% | Option 47.2 · PSU 17.6 · RSU 17.6 | No | Alpine Rewards |
| Olema Pharmaceuticals | 110% | Options 100 | not disclosed | Aon |
| Pacira BioSciences | 90% | RSU 80 · PSU 20 | No | Aon |
| Perspective Therapeutics | not disclosed | Options 100 | not disclosed | Aon |
| Pliant Therapeutics | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Pearl Meyer; Alpine Rewards |
| Precigen | 140% | not disclosed | not disclosed | Aon |
| PTC Therapeutics | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Puma Biotechnology | 169.7% | Options 50 · RSU 50 | not disclosed | Compensia |
| Replimune Group | not disclosed | not disclosed | No | Pearl Meyer |
| Supernus Pharmaceuticals | not disclosed | not disclosed | No | Aon |
| Vanda Pharmaceuticals | 108% | not disclosed | Yes — Relative TSR | Willis Towers Watson |
| Xencor | 110% | Options 60 · RSU 40 | not disclosed | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-27 | 73,322,772 | 10,862,168 | 4,822,016 | 87.1% | Passed |
| 2025 | 2025-06-11 | 19,179,927 | 16,164,644 | 3,583,400 | 54.27% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-27 | 87.1%a |
| 2025 | 2025-06-11 | 54.27%b |
a. Approved under the standard stated in the filing — “Abstentions will not be counted as votes cast on this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions will not be counted as votes cast on this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 225,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 402,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 125,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 400,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 125,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 402,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 402,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 225,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 402,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 450,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 400,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | A | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | D | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 500,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | D | 200,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | D | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | D | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 450,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Dennis M. Lanfear | Director | 2026-05-29 | A | 200,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | A | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | A | 15,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | A | 25,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | A | 100,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bryan McMichael | Chief Financial Officer | 2026-05-29 | A | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Mats Wahlstrom | Director | 2026-06-05 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jill O'Donnell-Tormey | Director | 2026-06-05 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Lee N. Newcomer, MD | Director | 2026-06-05 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lee N. Newcomer, MD | Director | 2026-06-05 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Ali J. Satvat | Director | 2026-06-05 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ali J. Satvat | Director | 2026-06-05 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Michael Ryan | Director | 2026-06-05 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jill O'Donnell-Tormey | Director | 2026-06-05 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles W. Newton | Director | 2026-06-05 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles W. Newton | Director | 2026-06-05 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Michael Ryan | Director | 2026-06-05 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Rita A. Karachun | Director | 2026-06-05 | A | 60,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mats Wahlstrom | Director | 2026-06-05 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
| Rita A. Karachun | Director | 2026-06-05 | A | 30,000 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (93 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Dennis Lanfear. DEF 14A, filed 2026-04-20. Section “Executive Compensation”. As printed: 2,736,874. View filing ↗
- Section 01, Paul Reider. DEF 14A, filed 2026-04-20. Section “Executive Compensation”. As printed: 1,227,524. View filing ↗
- Section 01, Bryan McMichael. DEF 14A, filed 2026-04-20. Section “Executive Compensation”. As printed: 1,103,077. View filing ↗
- Section 03, Bryan McMichael OPTION. DEF 14A, filed 2026-04-20. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Paul Reider OPTION. DEF 14A, filed 2026-04-20. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 03, Dennis Lanfear OPTION. DEF 14A, filed 2026-04-20. Section “Summary Compensation Table” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-20. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Mats L. Wahlström. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 191,667. View filing ↗
- Section 08, Charles W. Newton. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 144,167. View filing ↗
- Section 08, Ali J. Satvat. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 144,167. View filing ↗
- Section 08, Rita A. Karachun. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 139,167. View filing ↗
- Section 08, Georgia Erbez. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 134,167. View filing ↗
- Section 08, Michael Ryan. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 131,042. View filing ↗
- Section 08, Lee N. Newcomer, MD. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 121,667. View filing ↗
- Section 08, Jill O'Donnell-Tormey, Ph.D. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 116,667. View filing ↗
- Section 08, Mark D. Stolper. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 35,000. View filing ↗
- Section 08, Dennis M. Lanfear. DEF 14A, filed 2026-04-20. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Bryan McMichael 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bryan McMichael 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bryan McMichael 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bryan McMichael 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bryan McMichael 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bryan McMichael 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bryan McMichael 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dennis M. Lanfear 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bryan McMichael 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bryan McMichael 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bryan McMichael 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bryan McMichael 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bryan McMichael 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mats Wahlstrom 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jill O'Donnell-Tormey 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lee N. Newcomer, MD 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lee N. Newcomer, MD 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ali J. Satvat 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ali J. Satvat 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Ryan 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jill O'Donnell-Tormey 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles W. Newton 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles W. Newton 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Ryan 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rita A. Karachun 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mats Wahlstrom 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Rita A. Karachun 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-01. Item 5.07 · say-on-pay result. As reported: 87.1% (votes for as printed: 73,322,772). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-13. Item 5.07 · say-on-pay result. As reported: 54.27% (votes for as printed: 19,179,927). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 664,375 + equity 0 + all other 0 = 664,375, summed across the director compensation table rows.
- PTC Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in PTC Therapeutics's own proxy. As printed: 23,266,326. View filing ↗
- Supernus Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-03-27. CEO total compensation as printed in Supernus Pharmaceuticals's own proxy. As printed: 18,501,214. View filing ↗
- Pacira BioSciences, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Pacira BioSciences's own proxy. As printed: 11,636,917. View filing ↗
- Mirum Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Mirum Pharmaceuticals's own proxy. As printed: 10,441,224. View filing ↗
- Acadia Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals's own proxy. As printed: 8,256,518. View filing ↗
- Replimune Group, Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Replimune Group's own proxy. As printed: 5,845,982. View filing ↗
- Xencor, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Xencor's own proxy. As printed: 5,521,205. View filing ↗
- Pliant Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Pliant Therapeutics's own proxy. As printed: 5,462,901. View filing ↗
- Agios Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Agios Pharmaceuticals's own proxy. As printed: 5,370,389. View filing ↗
- Precigen, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Precigen's own proxy. As printed: 5,354,329. View filing ↗
- Cullinan Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Cullinan Therapeutics's own proxy. As printed: 5,100,006. View filing ↗
- Lyell Immunopharma, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Lyell Immunopharma's own proxy. As printed: 4,222,265. View filing ↗
- Vanda Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Vanda Pharmaceuticals's own proxy. As printed: 3,851,468. View filing ↗
- Heron Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Heron Therapeutics's own proxy. As printed: 3,516,291. View filing ↗
- Olema Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Olema Pharmaceuticals's own proxy. As printed: 3,178,990. View filing ↗
- Puma Biotechnology, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Puma Biotechnology's own proxy. As printed: 3,062,337. View filing ↗
- Cardiff Oncology, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Cardiff Oncology's own proxy. As printed: 3,023,344. View filing ↗
- Coherus Oncology, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in Coherus Oncology, Inc.'s own proxy. As printed: 2,736,874. View filing ↗
- Perspective Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Perspective Therapeutics's own proxy. As printed: 2,404,692. View filing ↗
- Karyopharm Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Karyopharm Therapeutics's own proxy. As printed: 2,320,902. View filing ↗
- Black Diamond Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Black Diamond Therapeutics's own proxy. As printed: 2,234,919. View filing ↗
- Actuate Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Actuate Therapeutics's own proxy. As printed: 2,166,522. View filing ↗
- Ironwood Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Ironwood Pharmaceuticals's own proxy. As printed: 1,948,390. View filing ↗
- Caribou Biosciences, Section 10b CEO total. DEFR 14A, filed 2026-05-01. CEO total compensation as printed in Caribou Biosciences's own proxy. As printed: 1,840,965. View filing ↗
- Collegium Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Collegium Pharmaceuticals's own proxy. As printed: 1,715,846. View filing ↗
- Section 10a, Heron Therapeutics reciprocity. DEF 14A. Heron Therapeutics names Coherus Oncology, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Puma Biotechnology reciprocity. DEF 14A. Puma Biotechnology names Coherus Oncology, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗